Persistent Pulmonary Artery Hypertension After Valve Replacement (SALT)
Recruitment status was Not yet recruiting
Background: Persistent severe pulmonary hypertension (PH) after mechanical valve replacement is a frequent finding in patients with severe valve-diseases. The reasons to develop PH are multifactorial and the prevalence of severe PH significantly worsens the patients´ outcome.
Aims: (i) To define the prevalence of PH in patients after valve replacement and (ii) to identify factors predicting persistent PH.
Methods: All patients which underwent valve replacement at our institution between the years 2008 -2010 will be screened retrospectively. Those patients with pre- procedural proven PH by means of right-heart catheterization will receive prospective follow-up with echocardiography. Diagnosis of persistent PH will be confirmed with right heart catheterization.
Persistent Severe PH After Valve Therapy
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||Persistence of Severe Pulmonary Artery Hypertension in Patients After vaLve replacemenT|
- Persistence of pulmonary hypertension after valve replacement for treatment of severe valve disease [ Time Frame: > 6 months after valve therapy ] [ Designated as safety issue: No ]
- MACCE, all cause mortality during FU [ Time Frame: Within 24 months after valve therapy ] [ Designated as safety issue: No ]
|Study Start Date:||January 2011|
|Estimated Study Completion Date:||March 2012|
|Estimated Primary Completion Date:||January 2011 (Final data collection date for primary outcome measure)|
Patients undergoing valve replacement for severe valve disease will be screened for study entry
Please refer to this study by its ClinicalTrials.gov identifier: NCT01238731
|Contact: Christoph Hammerstingl, MDemail@example.com|
|Contact: Dirk Skowasch, MD, PhDfirstname.lastname@example.org|
|Medizinische Klinik II, University of Bonn||Not yet recruiting|
|Bonn, Germany, 53125|
|Contact: Robert Schueler, MD +4922815507 email@example.com|
|Sub-Investigator: Stefan Pabst, MD|